In male patients with DMD, treatment with deramiocel reduced upper limb function deterioration compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...

Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017. ・Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), on Monday, announced positive data from its ongoing HOPE-2 open-label extension trial, demonstrating the long-term efficacy of Deramiocel for the ...

Capricor Therapeutics has submitted a Biologics License Application (BLA) to the FDA for deramiocel, an investigational cell therapy intended to treat Duchenne muscular dystrophy (DMD) cardiomyopathy, ...

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trial HOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmission Company preparing to resubmit CRL response ...

--At this time, FDA has not identified any potential review issues with the BLA-- SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company ...

Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022) Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017) Global Statistical ...

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

-Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...